dr. suresh ramalingam on hsp90 inhibition with ganetespib in lung cancer
Published 11 years ago • 217 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
2:53
dr. suresh ramalingam on hsp90 inhibition with ganetespib
-
0:59
dr. suresh ramalingam reviews the galaxy-1 trial results
-
1:23
dr. suresh ramalingam explores cytotoxics in lung cancer
-
5:59
asco 2013: ganetespib inhibits hsp90 with docetaxel for advanced lung cancer
-
1:21
dr. suresh s. ramalingam on optimizing immunotherapies in lung cancer
-
4:56
galaxy-1 trial: investigation of hsp90 inhibitors in nsclc
-
2:00
dr. ramalingam discusses hsp90 as treatment for lung cancer
-
2:04
dr. suresh ramalingam on frontline osimertinib data in egfr nsclc
-
0:56
dr. ramalingam on treatment parameters for osimertinib in lung cancer
-
7:59
asco 2013: suresh s. ramalingam, emory university in atlanta, ga.
-
1:43
dr. ramalingam discusses the results of the phase iii revel study in nsclc
-
3:05
suresh ramalingam discusses side effects associated with immunotherapy in lung cancer
-
1:19
dr. ramalingam on emerging combination regimens in nsclc
-
18:07
2020 winship scientific symposium | suresh ramalingam, md
-
0:57
dr. gandara on the heat shock protein 90 inhibitor ganetespib
-
7:39
suresh ramalingham, md: the role of parp inhibitors in lung cancer treatment
-
1:40
dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
-
0:34
dr. ramalingam on the safety of tecemotide
-
1:50
researcher comment: positive os data for osimertinib in flaura trial | suresh ramalingam